BRIEF published on 06/27/2024 at 18:20, 4 months 23 days ago Dermapharm Holding SE: Annual General Meeting Resolves Dividend Distribution of EUR 0.88 Per Share Annual General Meeting Dividend Financial Outlook Dermapharm
PRESS RELEASE published on 06/27/2024 at 18:15, 4 months 23 days ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share Dermapharm Holding SE's Annual General Meeting approves EUR 0.88 per share dividend distribution for 2024. Board actions confirmed. Outlook and acquisitions strategies highlighted Annual General Meeting Acquisitions Outlook Dividend Distribution Dermapharm Holding SE
BRIEF published on 05/15/2024 at 07:35, 6 months 6 days ago Dermapharm Holding SE Reports Decline in Q1 2024 Revenue Amidst Strong Branded Pharmaceuticals Growth Financial Results Organic Growth Market Resilience Healthcare Products Branded Pharmaceuticals
BRIEF published on 05/15/2024 at 07:35, 6 months 6 days ago Dermapharm Holding SE annonce une baisse de son chiffre d'affaires au premier trimestre 2024 dans un contexte de forte croissance des produits pharmaceutiques de marque Résultats Financiers Croissance Organique Résilience Du Marché Produits De Santé Produits Pharmaceutiques De Marque
PRESS RELEASE published on 05/15/2024 at 07:30, 6 months 6 days ago Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy Dermapharm Holding SE reports strong organic growth in core markets with resilient corporate strategy in Q1 2024 Organic Growth Q1 2024 Core Markets Dermapharm Holding SE Resilient Strategy
BRIEF published on 03/28/2024 at 07:35, 7 months 24 days ago Dermapharm Holding SE répond à toutes les attentes dans un contexte économique difficile Rapport Annuel 2023 Défis Économiques Dermapharm Holding SE Industrie Pharmaceutique Attentes De Croissance
BRIEF published on 03/28/2024 at 07:35, 7 months 24 days ago Dermapharm Holding SE Meets All Expectations in Challenging Economic Climate Pharmaceutical Industry Annual Report 2023 Economic Challenges Dermapharm Holding SE Growth Expectations
PRESS RELEASE published on 03/28/2024 at 07:30, 7 months 24 days ago Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges Dermapharm Holding SE fulfils all expectations in 2023 despite macroeconomic challenges, with revenue up by 10.8% to EUR 1,135.4 million and adjusted EBITDA margin at 27.3% Pharmaceutical Industry Revenue Growth EBITDA Margin Annual Report Dermapharm Holding SE
BRIEF published on 03/14/2024 at 07:35, 8 months 7 days ago Dermapharm Holding SE atteint l'extrémité supérieure de sa fourchette d'orientation malgré les défis Résultats Financiers Hausse Des Revenus Médicaments Dermapharm Holding SE Produits De Santé
BRIEF published on 03/14/2024 at 07:35, 8 months 7 days ago Dermapharm Holding SE Achieves Top End of Guidance Range Amid Challenges Financial Results Revenue Growth Pharmaceuticals Dermapharm Holding SE Healthcare Products
Published on 11/21/2024 at 12:00, 51 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 51 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 21 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 48 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 51 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 16 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 36 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 21 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 5 hours 53 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 53 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 53 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 44 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 31 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
